Moreover, PFE is making it tough on the generic competitors (and on managed-care plans) by funding patients’ copayments for branded Lipitor: http://www.bloomberg.com/news/2011-03-22/pfizer-lipitor-subsidy-may-affect-ranbaxy-deutsche-bank-says.html